MedPath

Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure

Phase 3
Completed
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Renal Failure
Registration Number
NCT00416897
Lead Sponsor
University of Glasgow
Brief Summary

RATIONALE: Dexamethasone is used to treat multiple myeloma. Drugs used in chemotherapy may stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Plasma exchange is a process in which certain cells are separated from the plasma in the blood by a machine and then only the cells are returned to the patient. Dexamethasone and plasma exchange may be an effective treatment for acute kidney failure caused by multiple myeloma. It is not yet known whether giving dexamethasone and chemotherapy together with plasma exchange is more effective than giving dexamethasone and chemotherapy alone in treating patients with multiple myeloma and acute kidney failure.

PURPOSE: This randomized phase III trial is studying dexamethasone, chemotherapy, and plasma exchange to see how well they work compared with dexamethasone and chemotherapy alone in treating patients with newly diagnosed multiple myeloma and acute kidney failure.

Detailed Description

OBJECTIVES:

Primary

* Compare the effect of dexamethasone and cytotoxic chemotherapy with vs without plasma exchange on the likelihood of renal recovery (i.e., dialysis-independent at 100 days) in patients with newly diagnosed multiple myeloma and acute renal failure.

Secondary

* Compare the overall survival of patients treated with these regimens.

* Compare the quality of life of patients treated with these regimens.

* Determine the value of renal histology in predicting recovery of renal function in these patients.

* Determine the value of serum free light chain assay in determining disease response and renal function recovery in these patients.

OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are stratified according to planned chemotherapy (vincristine and doxorubicin hydrochloride (VA) or VA-like chemotherapy vs thalidomide-containing chemotherapy vs alkylating agent vs other), frequency of chemotherapy courses (1-3 weekly vs 4 weekly), need for dialysis at randomization (yes vs no), and age (\< 65 years vs ≥ 65 years). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral dexamethasone, at least twice daily, on days 1-4 and 9-12. Patients undergo plasma exchange by cytocentrifugation or plasmafiltration over 2-3 hours in weeks 1 and 2 (7 treatments total; 4 of them in week 1). Patients then receive planned chemotherapy per local clinician on days 17-100. Chemotherapy may continue after 100 days at the discretion of the local clinician.

* Arm II: Patients receive dexamethasone and planned chemotherapy as in arm I. Quality of life is assessed at baseline, day 100, and 6 and 12 months.

After completion of study treatment, patients are followed at 6 and 12 months and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 280 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
280
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients alive and dialysis-independent at 100 days
Secondary Outcome Measures
NameTimeMethod
Proportion of patients alive and dialysis-independent at 6 and 12 months
Overall survival
Glomerular filtration rate (calculated or measured) at 15 and 100 days and at 6 and 12 months
Change in serum free light chain levels between days 0 and 15
Response of myeloma to treatment at 100 days and at 6 and 12 months
Quality of life

Trial Locations

Locations (39)

Basingstoke and North Hampshire NHS Foundation Trust

🇬🇧

Basingstoke, England, United Kingdom

Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

🇬🇧

Birmingham, England, United Kingdom

Good Hope Hospital

🇬🇧

Birmingham, England, United Kingdom

Birmingham Heartlands Hospital

🇬🇧

Birmingham, England, United Kingdom

Bradford Royal Infirmary

🇬🇧

Bradford, England, United Kingdom

Sussex Cancer Centre at Royal Sussex County Hospital

🇬🇧

Brighton, England, United Kingdom

Bristol Haematology and Oncology Centre

🇬🇧

Bristol, England, United Kingdom

Addenbrooke's Hospital

🇬🇧

Cambridge, England, United Kingdom

Kent and Canterbury Hospital

🇬🇧

Canterbury, England, United Kingdom

St. Helier Hospital

🇬🇧

Carshalton, England, United Kingdom

Scroll for more (29 remaining)
Basingstoke and North Hampshire NHS Foundation Trust
🇬🇧Basingstoke, England, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.